Miao Zukang, Han Zhiwei, Zheng Kai, Xu Ming, Yu Xue, Han Changsheng, Yu Xiuchun
Department of Orthopaedic Surgery, The 960th Hospital of the People's Liberation Army Joint Logistics Support Force, Jinan, Shandong, China.
Department of Joint Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Front Oncol. 2024 Sep 19;14:1402550. doi: 10.3389/fonc.2024.1402550. eCollection 2024.
Denosumab has recently become an important part of the treatment regime for spinal giant cell tumors of the bone (GCTB). Its use has significantly reduced the risk of surgery and postoperative complications in patients with spinal GCTB. However, the use of denosumab has not yet been optimized to reap the maximum benefits. Here, we have reported the case of a patient who was treated with denosumab in combination with excision and scraping for GCTB of the T10 vertebrae, which achieved good tumor control and no recurrence at the 2-year postoperative follow-up. We have also reviewed the case in the light of relevant literature as well as presented our ideas and recommendations for the optimal use of denosumab.
地诺单抗最近已成为脊柱骨巨细胞瘤(GCTB)治疗方案的重要组成部分。它的使用显著降低了脊柱GCTB患者的手术风险和术后并发症。然而,地诺单抗的使用尚未得到优化以获得最大益处。在此,我们报告了一例T10椎体GCTB患者,采用地诺单抗联合切除和刮除术进行治疗,术后2年随访实现了良好的肿瘤控制且无复发。我们还根据相关文献对该病例进行了回顾,并提出了关于地诺单抗最佳使用的想法和建议。